‘I still believe with the right dose in the right patient, there could be a way forward where there is less bleeding and preserving the ischemic benefit in a potent fashion.’ said Dr. Roxana Mehran in a conversation with Dr Vishal Rastogi at the annual India Live 2024.

Here are the top 5 takeaways:

1. Tailoring antiplatelet therapy: no one-size-fits-all
2. Drug-coated balloons may reduce dual antiplatelet therapy duration.
3. Thinking beyond antiplatelet therapy: managing LDL and A1C is crucial.
4. Drug-coated balloons: not for everyone, but useful in selected cases.
5. Aspirin-free strategies and factor XI inhibitors show promise.

Dr. Vishal Rastogi: 

Dr. Vishal Rastogi is a prominent interventional cardiologist and currently serves as the Director of Interventional Cardiology and the Head of the Advanced Heart Failure Program at Fortis Escorts Heart Institute in New Delhi. With over 20 years of experience, he specializes in complex coronary interventions, including techniques such as Rotablation, carotid intervention, and percutaneous aortic valve implantation.

Dr. Rastogi is particularly noted for his expertise in implanting the Impella Left Ventricular Assist Device, making him one of the most experienced practitioners in this area in India. He is also a national proctor for advanced coronary imaging techniques like IVUS (Intravascular Ultrasound) and OCT (Optical Coherence Tomography), as well as for dedicated bifurcation stents.
Dr. Rastogi is actively involved in clinical research, serving as a principal investigator for various interventional and heart failure trials, and he contributes to the academic community as a member of the editorial board of the Indian Heart Journal. His commitment to advancing cardiovascular care is reflected in his leadership roles and ongoing involvement in training other healthcare professionals.

Website: https://www.fortishealthcare.com/doctors/dr-vishal-rastogi-737

Dr. Roxana Mehran: 

Dr. Roxana Mehran is a distinguished Iranian-American cardiologist and the Mount Sinai Endowed Professor of Medicine at the Icahn School of Medicine at Mount Sinai in New York City. She is renowned for her expertise in interventional cardiology and her significant contributions to cardiovascular clinical research.
As of 2021, Dr. Mehran has been recognized for her extensive research, with over 200,000 citations and an h-index of 163, highlighting her influence in the field. She has served as a principal investigator for numerous clinical trials and is known for her work on outcomes research, particularly related to acute coronary syndromes and the prevention of acute kidney injury in cardiac patients.
Dr. Mehran is also an advocate for women in medicine, co-founding the organization Women as One, which aims to support female physicians. 

Website: https://profiles.mountsinai.org/roxana-mehran

Choosing the Right Antiplatelet Therapy: No One-Size-Fits-All

In an exclusive interview with TheRightDoctors on Emcure AICOG tv, Dr. C. N. Purandare, FIGO President, spoke about the increasing rates of caesarean section in India. This is what he said:

'In India the overall cesarean section rate is about 17.2% annually and it varies from city to city. W.H.O said that there should be between 10 and 15 to reduce maternal mortality.'

'There was a time and people said once a cesarean section not always cesarean section, which is a very disturbing trend as far as cesarean sections are concerned and I think today obstetrician need to really look at.'

'Today scenario no definitive number can be put as for cesarean section women who needs it must have it, FOGSI probably will follow what W.H.O and FIGO’s guidelines have now been accepted by W.H.O.'

'The W.H.O guidelines have also come out and as I categorically said that women in need must has a cesarean section.  There is no number unfortunately the 1985, 10-15% which was written by W.H.O is coated by everybody .'

'People feel that obstetrician do cesarean section because they are getting more money and there is money being exchange here 
FIGO has actually put in recommendation which I think all the obstetricians must start following that the charges for normal delivery and cesarean section the obstetrician charges should be same.'

'Nobody should say that you are charging more forceps cesarean section.  Of course, the normal delivery charges will to up because of standardization that will happen.'

Choosing the Right Antiplatelet Therapy: No One-Size-Fits-All

TheRightDoctors

Related tracks